Clinical trials: Advanced Solid Tumors Patients
Advanced Solid Tumor, Advanced Cancer
NBE-002 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04441099
- Testing
- NBE-002
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- NBE-Therapeutics AG
Malignant Solid Tumor, Solid Tumor
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
The purpose of this study is to evaluate two different dosing regimens of LY2334737 in participants with cancer that is advanced and/or has spread to other parts of the body. Information about side effects will be collected.
- Conditions
- Malignant Solid Tumor, Solid Tumor, Metastatic Tumor
- Trial name
- NCT01648764
- Testing
- LY2334737
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors
This study is a Phase 1b, single-center, open-label, dose-finding trial designed to identify the Recommended Phase 2 Dose (RP2D) of STI 6129 by assessing the safety, preliminary efficacy, and immunogenicity in subjects with any…
- Trial name
- NCT05584709
- Testing
- STI-6129
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sorrento Therapeutics, Inc.
Advanced Solid Tumor
Study of ZG0895.HCl in Patients With Advanced Solid Tumors
The primary objective of this study is to assess the tolerability and safety of ZG0895.HCl, and to assess the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) of ZG0895.HCl.
- Trial name
- NCT05877664
- Testing
- ZG0895 Hydrochloride for Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Melanoma, NSCLC
A Study of BCD-135 in Patients With Advanced Solid Tumors
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
- Conditions
- Melanoma, NSCLC, Renal Cell Carcinoma, Bladder Cancer
- Trial name
- NCT03464032
- Testing
- BCD-135
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Biocad
Advanced Solid Tumors
Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
This study is the first-in-human (Phase I/II) trial of SYS6045, a multicenter, open-label, dose-escalation and dose-expansion clinical study.
- Trial name
- NCT07122063
- Testing
- SYS6045
- Where
- China
- Volunteers
- 266 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Advanced Solid Tumours
Capivasertib China PK Study
This is an open-label, 2-part Phase I study to assess the PK, safety and tolerability of capivasertib as monotherapy and in combination with paclitaxel in Chinese participants with advanced solid tumours
- Trial name
- NCT04742036
- Testing
- Capivasertib, Paclitaxel
- Where
- China
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor, Metastatic Solid Tumor
Study of LP-184 in Patients With Advanced Solid Tumors
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT05933265
- Testing
- LP-184, Olaparib, Nivolumab & Ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 64 people
- Sponsor
- Lantern Pharma Inc.
Unspecified Adult Solid Tumor, Protocol Specific
SR-45023A in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of SR-45023A in treating patients who have advanced solid…
- Trial name
- NCT00003822
- Testing
- apomine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced Solid Tumor Cancer
A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors
This is an open-label, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of YF087 in subjects with Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) advanced solid…
- Trial name
- NCT07809607
- Testing
- YF087
- Volunteers
- 70 people
- Sponsor
- InventisBio Co., Ltd
Neoplasms
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.
This 3 arm study will determine the dose of R1507 which will achieve a mean drug exposure in children and adolescents with advanced solid tumors equivalent to the exposure achieved in adults at the recommended dose of…
- Trial name
- NCT00560144
- Testing
- RG1507
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Advanced Malignant Solid Tumor
A Study of MHB042C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB042C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07192107
- Testing
- MHB042C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Solid Tumors
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors
This study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-ARC002 for…
- Trial name
- NCT07591155
- Testing
- BL-ARC002
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
NSCLC, Prostate Cancer
Clinical Trial of TB511 in Advanced Solid Tumors
1. Study population [TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC).
- Conditions
- NSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06400160
- Testing
- TB511, Keytruda
- Volunteers
- 12 people
- Sponsor
- Twinpig Biolab, Inc.
Cancer
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
Assess the safety and tolerance of a weekly MEDI522 regimen in patients with irinotecan-refractory advanced CRC or other solid tumors refractory to standard therapy.
- Trial name
- NCT00284817
- Testing
- MEDI-522
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- MedImmune LLC
Advanced or Metastatic Solid Tumors
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.
This is an open label, two-part, multicenter, multi-regional phase I trial to investigate the safety, tolerability, and PK of KGX101 monotherapy and combination therapy with Envafolimab in patients with advanced or metastatic…
- Trial name
- NCT06074497
- Testing
- KGX101- Cohort -1, KGX101- Cohort 1, KGX101- Cohort 2
- Where
- 3 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Kangabio AUSTRALIA LTD PTY
Cancer
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
Study to access the safety, levels of drug in the blood and tumor effects of sorafenib dosed daily combined with Cyclophosphamide and Doxorubicin in cancer patients
- Trial name
- NCT00562913
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 2 sites in Canada
- Volunteers
- 21 people
- Sponsor
- Bayer
Malignant Solid Tumor
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102.
- Trial name
- NCT01457118
- Testing
- NKTR-102 145 mg/m2, NKTR-102 120 mg/m2, NKTR-102 95 mg/m2
- Where
- 7 sites in United States, Belgium
- Volunteers
- 27 people
- Sponsor
- Nektar Therapeutics
Advanced Solid Tumours, Breast Cancer
The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
This is a phase 1, First-In-Human, open label study, trialing a new PARP (poly-ADP ribose polymerase) inhibitor medication IMP4297 in participants with advanced solid tumour.
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03507543
- Testing
- IMP4297
- Where
- 3 sites in Australia
- Volunteers
- 39 people
- Sponsor
- Impact Therapeutics, Inc.
Neoplasms
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
This open label Phase 1 study involves treating subjects with advanced cancer with BAY80-6946 in combination with paclitaxel. It will determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of…
- Trial name
- NCT01411410
- Testing
- Paclitaxel, Copanlisib (BAY80-6946)
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.